|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OSBPL9 |
Gene summary for OSBPL9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OSBPL9 | Gene ID | 114883 |
| Gene name | oxysterol binding protein like 9 | |
| Gene Alias | ORP-9 | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q96SU4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114883 | OSBPL9 | CCI_1 | Human | Cervix | CC | 5.49e-04 | 8.17e-01 | 0.528 |
| 114883 | OSBPL9 | CCI_3 | Human | Cervix | CC | 1.78e-10 | 7.20e-01 | 0.516 |
| 114883 | OSBPL9 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.44e-16 | -6.25e-01 | 0.0155 |
| 114883 | OSBPL9 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.96e-08 | -5.03e-01 | 0.096 |
| 114883 | OSBPL9 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.84e-07 | -5.94e-01 | 0.0338 |
| 114883 | OSBPL9 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.20e-03 | -3.80e-01 | 0.0674 |
| 114883 | OSBPL9 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.26e-02 | -4.66e-01 | 0.0588 |
| 114883 | OSBPL9 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.39e-05 | -3.71e-01 | 0.294 |
| 114883 | OSBPL9 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.25e-04 | -3.85e-01 | 0.3859 |
| 114883 | OSBPL9 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.39e-06 | -6.73e-01 | 0.2585 |
| 114883 | OSBPL9 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.20e-17 | -5.95e-01 | 0.3005 |
| 114883 | OSBPL9 | F007 | Human | Colorectum | FAP | 3.74e-05 | -4.91e-01 | 0.1176 |
| 114883 | OSBPL9 | A002-C-010 | Human | Colorectum | FAP | 2.05e-05 | -3.28e-01 | 0.242 |
| 114883 | OSBPL9 | A001-C-207 | Human | Colorectum | FAP | 2.82e-02 | -3.16e-01 | 0.1278 |
| 114883 | OSBPL9 | A015-C-203 | Human | Colorectum | FAP | 6.93e-27 | -4.88e-01 | -0.1294 |
| 114883 | OSBPL9 | A015-C-204 | Human | Colorectum | FAP | 8.04e-11 | -5.07e-01 | -0.0228 |
| 114883 | OSBPL9 | A014-C-040 | Human | Colorectum | FAP | 2.17e-06 | -5.39e-01 | -0.1184 |
| 114883 | OSBPL9 | A002-C-201 | Human | Colorectum | FAP | 3.89e-16 | -4.82e-01 | 0.0324 |
| 114883 | OSBPL9 | A002-C-203 | Human | Colorectum | FAP | 3.86e-06 | -2.76e-01 | 0.2786 |
| 114883 | OSBPL9 | A001-C-119 | Human | Colorectum | FAP | 6.61e-09 | -5.25e-01 | -0.1557 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:0008202 | Colorectum | AD | steroid metabolic process | 85/3918 | 319/18723 | 8.07e-03 | 4.75e-02 | 85 |
| GO:0046394 | Colorectum | MSS | carboxylic acid biosynthetic process | 76/3467 | 314/18723 | 6.71e-03 | 4.38e-02 | 76 |
| GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
| GO:0016053 | Colorectum | MSS | organic acid biosynthetic process | 76/3467 | 316/18723 | 7.88e-03 | 4.84e-02 | 76 |
| GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
| GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
| GO:00068692 | Colorectum | CRC | lipid transport | 63/2078 | 398/18723 | 2.36e-03 | 2.26e-02 | 63 |
| GO:00108763 | Colorectum | CRC | lipid localization | 68/2078 | 448/18723 | 4.60e-03 | 3.58e-02 | 68 |
| GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
| GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
| GO:00066946 | Esophagus | ESCC | steroid biosynthetic process | 98/8552 | 173/18723 | 2.34e-03 | 1.03e-02 | 98 |
| GO:19016174 | Esophagus | ESCC | organic hydroxy compound biosynthetic process | 128/8552 | 237/18723 | 5.86e-03 | 2.16e-02 | 128 |
| GO:00160535 | Liver | NAFLD | organic acid biosynthetic process | 77/1882 | 316/18723 | 1.03e-13 | 6.69e-11 | 77 |
| GO:00463945 | Liver | NAFLD | carboxylic acid biosynthetic process | 75/1882 | 314/18723 | 6.37e-13 | 3.39e-10 | 75 |
| GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
| GO:0008206 | Liver | NAFLD | bile acid metabolic process | 19/1882 | 49/18723 | 9.82e-08 | 7.76e-06 | 19 |
| GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
| GO:00723303 | Liver | NAFLD | monocarboxylic acid biosynthetic process | 46/1882 | 214/18723 | 5.06e-07 | 3.07e-05 | 46 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OSBPL9 | SNV | Missense_Mutation | novel | c.1926N>C | p.Lys642Asn | p.K642N | Q96SU4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| OSBPL9 | SNV | Missense_Mutation | novel | c.1260N>A | p.Phe420Leu | p.F420L | Q96SU4 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OSBPL9 | SNV | Missense_Mutation | novel | c.1316N>A | p.Arg439Gln | p.R439Q | Q96SU4 | protein_coding | deleterious(0) | possibly_damaging(0.643) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OSBPL9 | SNV | Missense_Mutation | c.299N>A | p.Arg100Gln | p.R100Q | Q96SU4 | protein_coding | deleterious(0.01) | possibly_damaging(0.67) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| OSBPL9 | SNV | Missense_Mutation | novel | c.848C>T | p.Pro283Leu | p.P283L | Q96SU4 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BS-A0VI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OSBPL9 | SNV | Missense_Mutation | c.1052N>A | p.Ser351Tyr | p.S351Y | Q96SU4 | protein_coding | tolerated(0.09) | possibly_damaging(0.816) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OSBPL9 | SNV | Missense_Mutation | novel | c.1316N>A | p.Arg439Gln | p.R439Q | Q96SU4 | protein_coding | deleterious(0) | possibly_damaging(0.643) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OSBPL9 | SNV | Missense_Mutation | novel | c.512N>G | p.Lys171Arg | p.K171R | Q96SU4 | protein_coding | tolerated(0.48) | possibly_damaging(0.505) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| OSBPL9 | SNV | Missense_Mutation | novel | c.1965N>T | p.Lys655Asn | p.K655N | Q96SU4 | protein_coding | tolerated(0.38) | benign(0.062) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| OSBPL9 | SNV | Missense_Mutation | novel | c.172N>G | p.Ile58Val | p.I58V | Q96SU4 | protein_coding | tolerated(0.11) | probably_damaging(0.986) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |